Valuation: Exact Sciences Corporation

Market Cap 20.03B 17.58B 16.52B 15.11B 28.23B 1,918B 28.44B 198B 76.94B 978B 75.2B 73.56B 3,171B P/E 2024
-10.1x
P/E 2025 -92.2x
Enterprise Value 21.6B 18.95B 17.82B 16.29B 30.44B 2,069B 30.67B 214B 82.97B 1,055B 81.1B 79.32B 3,420B EV / Sales 2024
4.4x
EV / Sales 2025 6.42x
Free-Float
98.24%
Yield 2024 *
-
Yield 2025 -
1 day+0.95%
Current year+3.30%
Current year 101.51
Extreme 101.51
104.98
1 year 52.39
Extreme 52.39
104.98
3 years 38.81
Extreme 38.8118
104.98
5 years 29.27
Extreme 29.27
104.98
10 years 13.05
Extreme 13.05
159.54
Date Insider Type Main position Quantity % Market Cap. Importance
3/23/26 A Issuer sale

Director

28,899 0.0151%
3/23/26 A Free

Executive/Senior Manager

199,374 0.1044%
3/23/26 A Issuer sale

Director

20,558 0.0108%
Change 5-day change 1-year change 3-year change Capi.($)
+0.95%-.--%+100.17%+56.93% 20.03B
+2.40%+1.35%+379.01%+122.21% 4.62B
+2.74%-0.39%+121.84%+459.84% 4.45B
+4.69%+12.60%+39.78%+103.29% 3.52B
+9.77%+9.14%+293.36%+675.39% 2.81B
+2.50%+22.28%-7.77%-15.52% 2.52B
+0.89%+6.59%+48.11% - 1.69B
-0.58%+4.78%+29.52%+61.14% 1.13B
+0.07%+0.83%+169.49%-21.18% 1.1B
+5.08%+4.75%-20.77%+84.39% 625M
Average +2.73%+4.19%+115.27%+169.61% 4.25B
Weighted average by Cap. +2.17%+2.62%+130.17%+148.83%

Financials

2024 2025
Net sales 2.76B 2.42B 2.28B 2.08B 3.89B 264B 3.92B 27.34B 10.6B 135B 10.36B 10.13B 437B 3.25B 2.85B 2.68B 2.45B 4.58B 311B 4.61B 32.18B 12.47B 159B 12.19B 11.93B 514B
Net income -1.03B -903M -849M -776M -1.45B -98.56B -1.46B -10.2B -3.95B -50.25B -3.86B -3.78B -163B -208M -183M -172M -157M -293M -19.92B -295M -2.06B -799M -10.16B -781M -764M -32.93B
Net Debt 1.74B 1.53B 1.43B 1.31B 2.45B 166B 2.47B 17.22B 6.68B 84.87B 6.53B 6.38B 275B 1.57B 1.38B 1.3B 1.18B 2.21B 150B 2.23B 15.56B 6.03B 76.68B 5.9B 5.77B 249B
Logo Exact Sciences Corporation
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. It offers a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. Its portfolio includes brands such as Cologuard and Oncotype DX, along with solutions like Cancerguard for blood-based analysis of molecular information across multiple cancers and Oncodetect for molecular residual disease and recurrence monitoring. Its flagship screening products, the Cologuard and Cologuard Plus tests, are patient-friendly, non-invasive, stool-based DNA (sDNA) screening tests that utilize a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Its Cancerguard test is designed to detect multiple cancers in their earliest stages from a single blood draw. It offers predefined genetic tests for all clinically relevant genes, and whole genome (PGnome) sequencing tests.
Employees
7,150
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
AAA
  1. Stock Market
  2. Stocks
  3. EXAS Stock